Key result
Elevated serum levels of HDAC3 (HR 1.069) and TSP-1 (HR 1.242) were independent risk factors for poor prognosis in patients with chronic heart failure, and their combined detection yielded an AUC of 0.905.
Why the study?
The relations of serum HDAC3 and TSP-1 levels to cardiac function grades, ventricular remodeling, and prognosis in patients with chronic heart failure were not well characterized.
Do elevated serum levels of HDAC3 and TSP-1 predict poor prognosis and ventricular remodeling in patients with chronic heart failure?
Cohort (n=230)
No
Do elevated serum levels of HDAC3 and TSP-1 predict poor prognosis and ventricular remodeling in patients with chronic heart failure?
Combined detection of serum HDAC3 and TSP-1 levels may serve as a valuable biomarker panel for predicting ventricular remodeling and poor prognosis in patients with chronic heart failure.
Answers are grounded in this paper and cite their sources.
Serum HDAC3 and TSP-1 levels associated with CHF severity and prognosis; leaves open their incremental prognostic value.
BACKGROUND: This study aims to analyze the relations of serum Histone Deacetylase 3 (HDAC3) and Thrombospondin-1 (TSP-1) levels to cardiac function grades, ventricular remodeling, and prognosis of patients with chronic heart failure (CHF). METHODS: We conducted a retrospective analysis of 128 enrolled CHF patients, with 102 healthy individuals as controls. Baseline data and two-year follow-up records were collected to assess prognosis. Serum levels of HDAC3 and TSP-1 were measured using ELISA, and their correlations with ventricular remodeling indicators such as LVEF, LVEDD, LVFS, BNP, NT-proBNP, and cTnI were analyzed using Pearson's correlation coefficient. RESULTS: No significant differences were observed among participants in terms of age, gender, BMI, comorbidities, smoking history, and drinking history. CHF patients exhibited significantly reduced LVEF and LVFS, while LVEDD, BNP, NT-proBNP, cTnI levels, and serum levels of HDAC3 and TSP-1 were markedly elevated. It was found that serum levels of HDAC3 and TSP-1 increased with worsening cardiac function. Both of them correlated significantly with ventricular remodeling indicators, and their elevation was an independent risk factor for poor prognosis in CHF patients. CONCLUSION: Serum levels of HDAC3 and TSP-1 are elevated in CHF patients, exhibiting significant correlations with ventricular remodeling indicators. Combined detection of these two markers may assist in predicting poor prognosis in CHF patients.
No takes yet. Share an insight, caveat, or question.
Tao Cheng (2025) conducted a cohort in Chronic heart failure (n=230). Serum HDAC3 and TSP-1 levels vs. Lower biomarker levels was evaluated on Poor prognosis at 2 years (disease progression, readmission for worsening heart failure, cardiovascular death, or all-cause mortality) (HR 1.069, 95% CI 1.011-1.130, p=0.018). Elevated serum levels of HDAC3 (HR 1.069) and TSP-1 (HR 1.242) were independent risk factors for poor prognosis in patients with chronic heart failure, and their combined detection yielded an AUC of 0.905.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: